Join the Olaparib group to help and get support from people like you.
Olaparib News
FDA Approves Lynparza (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lynparza combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial First approval of a PARP inhibitor in combination...
Lynparza Approved in the US as Adjuvant Treatment for Patients with Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
First and only approved medicine targeting BRCA mutations in early breast cancer New data show Lynparza demonstrated overall survival benefit in early breast cancer March 11, 2022 – A...
Lynparza Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
20 May 2020 – AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for...
Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
30 December 2019 – AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Lynparza® (olaparib) has been approved in the US for ...
Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
19 December 2018 – AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as...
FDA Approves Lynparza (olaparib tablets) for Germline BRCA-Mutated Metastatic Breast Cancer
January 12, 2018 – The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that...
FDA Approves Tablet Formulation of Lynparza (olaparib) for Maintenance Treatment of Ovarian Cancer
August 17, 2017 – AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Ovarian Cancer, Breast Cancer, Breast Cancer, Metastatic, Prostate Cancer